Successful Anti-TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental Glomerulosclerosis

被引：42

作者：

Leroy, S. ^{[1
,5
]}

Guigonis, V. ^{[2
]}

Bruckner, D. ^{[1
,5
]}

Emal-Aglae, V. ^{[3
]}

Deschenes, G. ^{[4
]}

Bensman, A. ^{[1
,5
]}

Ulinski, T. ^{[1
,5
]}

机构：

[1] Armand Trousseau Hosp, AP HP, Dept Pediat Nephrol, Paris, France

[2] CHU Dupuytren, Dept Pediat, Limoges, France

[3] Dept Nephrol, Le Lamentin, Pointe A Pitre, France

[4] Hop Robert Debre, AP HP, Dept Pediat Nephrol, F-75019 Paris, France

[5] Univ Paris, F-75252 Paris, France

来源：

AMERICAN JOURNAL OF TRANSPLANTATION | 2009年 / 9卷 / 04期

关键词：

Anti-tumor necrosis factor-alpha treatment; nephrotic syndrome; posttransplant recurrence; steroid resistance; NECROSIS-FACTOR-ALPHA; NEPHROTIC SYNDROME; RENAL-ALLOGRAFTS; PLASMAPHERESIS; PROTEINURIA; GLOMERULI;

D O I：

10.1111/j.1600-6143.2009.02550.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Posttransplant recurrence of focal and segmental glomulosclerosis (FSGS) occurs in similar to 30% of patients, and remains after uncontrolled despite increased immunosuppression and plasma exchanges (PE) in similar to 30% of cases. New immunosuppressive drugs might then be warranted. We report the case of a 15-year-old boy with FSGS leading to end-stage renal disease (ESRD) who presented with an early posttransplant recurrence of disease. Reinforced immunosuppression and PE resulted in partial and transient disease control, but proteinuria significantly decreased with anti-TNF alpha treatment (infliximab then etanercep). This is the first case report of successful anti-TNF alpha treatment despite a constant high activity of FSGS, as demonstrated by relapse after discontinuation of anti-TNF alpha agents.

引用

页码：858 / 861

页数：4

共 16 条

[1] PLASMAPHERESIS REDUCES PROTEINURIA AND SERUM CAPACITY TO INJURE GLOMERULI IN PATIENTS WITH RECURRENT FOCAL GLOMERULOSCLEROSIS [J].

ARTERO, ML ;

SHARMA, R ;

SAVIN, VJ ;

VINCENTI, F .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (04) :574-581

[2] Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome [J].

Bakr, A ;

Shokeir, M ;

El-Chenawi, F ;

El-Husseni, F ;

Abdel-Rahman, A ;

El-Ashry, R .

PEDIATRIC NEPHROLOGY, 2003, 18 (06) :516-520

[3] Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial [J].

Busund, R ;

Koukline, V ;

Utrobin, U ;

Nedashkovsky, E .

INTENSIVE CARE MEDICINE, 2002, 28 (10) :1434-1439

[4] Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis [J].

Cheong, HI ;

Han, HW ;

Park, HW ;

Ha, IS ;

Han, KS ;

Lee, HS ;

Kim, SJ ;

Choi, Y .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (01) :78-81

[5] Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome [J].

Drewe, E ;

McDermott, EM ;

Powell, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (14) :1044-1045

[6] Recurrent focal glomerulosclerosis in pediatric renal allografts:: the Miami experience [J].

Hubsch, H ;

Montané, B ;

Abitbol, C ;

Chandar, J ;

Shariatmadar, S ;

Ciancio, G ;

Burke, G ;

Miller, J ;

Strauss, J ;

Zilleruelo, G .

PEDIATRIC NEPHROLOGY, 2005, 20 (02) :210-216

[7]

Kamanna VS, 1996, J AM SOC NEPHROL, V7, pA2159

[8]

McCarthy ET, 1998, J AM SOC NEPHROL, V9, P433

[9] Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment [J].

Pescovitz, MD ;

Book, BK ;

Sidner, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (18) :1961-1963

[10] RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN RENAL-ALLOGRAFTS [J].

PINTO, J ;

LACERDA, G ;

CAMERON, JS ;

TURNER, DR ;

BEWICK, M ;

OGG, CS .

TRANSPLANTATION, 1981, 32 (02) :83-89

← 1 2 →